Formycon AG AGM Greenlights Board Expansion Amid FYB Strategy Shift | SDAX TecDAX Update

June 19, 2025 03:03 PM AEST | By Team Kalkine Media

Formycon AG AGM Greenlights Board Expansion Amid FYB Strategy Shift | SDAX TecDAX Update — Image source: Shutterstock

Company Performance and Strategic Developments Detailed

The Management Board presented a comprehensive overview of operations during the 2024 fiscal period. Emphasis was placed on Formycon’s transition into a more commercially active biosimilar company, expanding from a purely development-focused model. The shift included enhanced revenue streams driven by licensing and strategic global collaborations.

In addition to outlining financial milestones, the board also laid out projections for the current year, with a focus on maturing pipeline assets and leveraging international commercialization efforts.

Supervisory Board Gains New Insight with Expansion

A pivotal outcome of the AGM was the expansion of Formycon’s Supervisory Board to accommodate six members. This change aims to strengthen oversight capabilities following the company’s Prime Standard listing and its broader operational scope.

Klaus Röhrig, associated with Active Ownership Capital, was re-elected following the conclusion of his previous term. In a complementary move, Dr. Graham Keith Dixon, currently leading Estetra SRL, was appointed as a new Supervisory Board member. This addition signals a strategic focus on broadening international governance perspectives and sectoral expertise within the board.

Governance Highlights and Shareholder Participation

Formal discharge of responsibilities for both the Management and Supervisory Boards received high shareholder approval during the session. The AGM witnessed notable participation, with a significant portion of voting share capital represented.

Chairman Wolfgang Essler, representing ATHOS KG, acknowledged the collective commitment to Formycon’s evolving strategy and praised the newly appointed and returning board members for their expected contributions to continued organizational development.

Strengthening Market Presence in Biosimilar Development

Formycon’s operational footprint continues to extend across therapeutic areas such as ophthalmology, immunology, and immuno-oncology. Its existing biosimilar portfolio, featuring approved therapies like FYB201/ranibizumab and FYB202/ustekinumab, is supported by ongoing pipeline advancements. With regulatory green lights in key global markets, the company is positioned to address increasing demand for accessible and affordable treatments.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.